Actively Recruiting
Plasma Metabolomic and Lipidomic Study to Predict Immune-Related Side Effects in Gastric Cancer Patients Receiving PD-1PD-L1 Immunotherapy
Led by Qinghai Red Cross Hospital · Updated on 2025-04-08
100
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating metabolic and lipidomic changes in patients with gastric cancer who are starting treatment with PD-1PD-L1 inhibitors. This observational study aims to identify metabolic and lipid biomarkers linked to immune-related adverse events irAEs and to develop models that predict the risk of these events. The goal is to improve personalized treatment approaches and clinical decisions in immunotherapy for gastric cancer. Patients with gastric cancer who have not yet received PD-1PD-L1 inhibitors are enrolled and plasma samples are collected before starting immunotherapy. For patients who develop irAEs, plasma samples are taken at the onset of these events. For those without irAEs, samples are collected based on treatment cycles matched to those with irAEs. Comprehensive analyses of metabolites and lipids in plasma samples are performed to detect differences related to irAEs and to build predictive risk models. Participants undergo regular plasma sampling and clinical monitoring over the course of one year to assess immune-related adverse events and molecular changes. Quality-of-life data and adverse event severity are also tracked. The study evaluates the associations between metabolic profiles and long-term patient outcomes, with follow-up and data collection continuing up to two years to support prognostic evaluations and clinical decision-making.
CONDITIONS
Brief Title
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here